The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma

European Journal of Gynaecological Oncology

Volumn 26, Issue 1, 2005, Pages 64-70

  Osmanagaoglul M A ^a,b   Kadioglu S ^a   Osmanagaoglu S ^a   Bozkaya, H ^a   Reis, A ^a   Tekelioglu Y ^a  

^a Department of Obstetrics ^*  (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

DNA ploidy; Endometrial cancer; p53; Prognostic factors

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA CONTENT; ENDOMETRIUM CARCINOMA; FEMALE; FISHER EXACT TEST; FLOW CYTOMETRY; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; PLOIDY; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEDICAL RECORDS; MIDDLE AGED; PLOIDIES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TURKEY;

EID: 14644437019     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J.: "Cancer statistics". Cancer J. Clin., 2003, 53, 5.
2. Lanciano R.M., Corn B.W., Schultz D.J., Kramer C.A., Rosenblum N., Hogan W.M.: "The justification for a surgical staging system in endometrial carcinoma". Radiother. Oncol., 1993, 28, 189.
3. Mayr N.A., Wen B.C., Benda J.A., Sorosky J.I., Davis C.S., Fuller R.W. et al.: "Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement-patterns of failure". Radiology, 1995, 196, 323.
4. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M. et al.: "WAF1, a potential mediator of p53 tumor suppression". Cell., 1993, 75, 817.
5. Harris C.C.: "Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies". J. Natl. Cancer Inst., 1996, 88, 1442.
6. Ito K., Watanabe K., Nasim S., Sasano H., Sato S., Yajima A. et al.: "Prognostic significance of p53 overexpression in endometrial cancer". Cancer Res., 1994, 54, 4667.
7. Kohlberger P., Gitsch G., Loesch A., Tempfer C., Kaider A., Reinthaller A. et al.: "p53 protein overexpression in early stage endometrial cancer". Gynecol. Oncol., 1996, 62, 213.
8. Geisler J.P., Wiemann M.C., Zhou Z., Miller G.A., Geisler H.E.: "p53 as a prognostic indicator in endometrial cancer". Gynecol. Oncol., 1996, 61, 245.
9. Lukes A.S., Kohler M.F., Pieper C.F., Kerns B.J., Bentley R., Rodriguez G.C. et al.: "Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer". Cancer, 1994, 73, 2380.
10. Ambros R.A., Sheehan C.E., Kallakury B.V., Ross J.S., Malfetano J., Paunovich E. et al.: "MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma". Mod. Pathol., 1996, 9, 1165.
11. Kohler M.F., Berchuck A., Davidoff A.M., Humphrey P.A., Dodge R.K., Iglehart J.D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 52, 1622.
12. Hamel N.W., Sebo T.J., Wilson T.O., Keeney G.L., Roche P.C., Suman V.J. et al.: "Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma". Gynecol. Oncol., 1996, 62, 192.
13. Reinartz J.J., George E., Lindgren B.R., Niehans G.A.: "Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival". Hum. Pathol., 1994, 25, 1075.
14. Erdem O., Erdem M., Dursun A., Akyol G., Erdem A.: "Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables". Int. J. Gynecol. Pathol., 2003, 22, 254.
15. Nielsen A.L., Nyholm H.C.: "p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections". Am. J. Clin. Pathol., 1994, 102, 76.
16. Lundgren C., Auer G., Frankendal B., Moberger B., Nilsson B., Nordstrom B.: "Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma". Int. J. Gynecol. Cancer, 2002, 12, 110.
17. Nordstrom B., Strang P., Lindgren A., Bergstrom R., Tribukait B.: "Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression". Anticancer Res., 1996, 16, 899.
18. Britton L.C., Wilson T.O., Gaffey T.A., Cha S.S., Wieand H.S., Podratz K.C.: "DNA ploidy in endometrial carcinoma: major objective prognostic factor". Mayo Clin. Proc., 1990, 65, 643.
19. Hedley D.W., Friedlander M.L., Taylor I.W., Rugg C.A., Musgrove E.A.: "Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry". J. Histochem. Cytochem., 1983, 31, 1333.
20. Strang P., Nordstom B., Nilsson S., Bergstrom R., Tribukait B.: "Mutant p53 protein as a predictor of survival in endometrial carcinoma". Eur. J. Cancer, 1996, 32, 598.
21. Nielsen A.L., Nyholm H.C.: "The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB- 1 and PC 10; suppressor oncogene protein: p53; oncogene protein: p 185 and age, hormone treatment, stage, and histologic grade". Eur. J. Obstet. Gynecol. Reprod. Biol., 1996, 70, 79.
22. Pfisterer J., Kommoss F., Sauerbrei W., Renz H., du Bois A., Kiechle-Schwarz M. et al.: "Prognostic value of DNA ploidy and S-phase fraction in Stage I endometrial carcinoma". Gynecol. Oncol., 1995, 58, 149.
23. Lindahl B., Alm P., Ferno M., Killander D., Langstrom E., Norgren A. et al.: "Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in Stage I-II endometrial carcinoma". Acta Oncol., 1989, 28, 595.
24. Rosenberg P., Wingren S., Simonsen E., Stal O., Risberg B., Nordenskjold B.: "Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator". Gynecol. Oncol., 1989, 35, 50.
25. Newbury R., Schuerch C., Goodspeed N., Fanning J., Glidewell O., Evans M.: "DNA content as a prognostic factor in endometrial carcinoma". Obstet. Gynecol., 1990, 76, 251.
26. Riethdorf L., Begemann C., Riethdorf S., Milde-Langosch K., Loning T.: "Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis". Virchows Arch., 1996, 428, 47.
27. Iversen O.E.: "Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma". Am. J. Obstet. Gynecol., 1986, 155, 770.
28. Larson D.M., Berg R., Shaw G., Krawisz B.R.: "Prognostic significance of DNA ploidy in endometrial cancer". Gynecol. Oncol., 1999, 74, 356.
29. Susini T., Rapi S., Massi D., Savino L., Amunni G., Taddei G.L. et al.: "Preoperative evaluation of tumor ploidy in endometrial carcinoma: An accurate tool to identify patients at risk for extrauterine disease and recurrence". Cancer, 1999, 86, 1005.